NASDAQ$PCVX
Vaxcyte Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Vaxcyte reported fourth quarter and full year 2021 financial results and provided a business update.
Vaxcyte announced its Q4 and full year 2021 financial results, highlighting the completion of VAX-24 drug product manufacturing and the initiation of a Phase 1/2 clinical study for VAX-24. The company's cash, cash equivalents, and investments totaled $273.1 million as of December 31, 2021, excluding net proceeds from a recent public offering.
- Completed the manufacture of VAX-24 drug product.
- Dosed first participants in VAX-24 Phase 1/2 clinical study.
- Advanced and presented preclinical data for VAX-XP program.
- Initiated VAX-A1 IND-enabling activities.
Headline financials
Revenue & EPS history
Vaxcyte · Revenue · Quarterly
$0
Forward guidance
Vaxcyte anticipates several key milestones for its vaccine programs, including VAX-24, VAX-XP, VAX-A1 and VAX-PG.
Tailwinds
- Topline safety, tolerability and immunogenicity results from the VAX-24 Phase 1/2 clinical study by the end of 2022.
- Begin enrollment in a separate Phase 2 study in healthy adults aged 65 and older upon successful completion of the Phase 1 portion of the recently initiated Phase 1/2 study in adults aged 18 to 64.
- Topline safety, tolerability and immunogenicity results from Phase 2 study in adults aged 65 and older are expected to be announced in the first half of 2023.
- Submit its first VAX-24 pediatric IND application to the FDA in the first half of 2023, subject to a pre-IND meeting with the FDA and successful topline results from the VAX-24 Phase 1/2 study in adults 18 to 64 years of age.
- Provide guidance for the anticipated submission of its IND application in adults to the FDA following the announcement of the topline results from the VAX-24 Phase 1/2 study in adults aged 18 to 64 for VAX-XP.
Headwinds
- Potential delays in development timelines.
- Inability to obtain and maintain required regulatory approvals for its vaccine candidates.
- Risks and uncertainties inherent with preclinical and clinical development processes.
- Impacts of COVID-19.
- Sufficiency of cash and other funding to support Vaxcyte’s development programs and other operating expenses.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+0.6%
Avg return
Earnings day
+0.8%
Avg return
5 days after
-0.2%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+23.8%
Q2 2020
Best reaction
-21.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.7% | +1.0% | -13.3% | |
| Q3 2025 | -2.5% | +3.8% | +12.4% | |
| Q2 2025 | -9.1% | -9.1% | +0.1% | |
| Q1 2025 | +8.3% | +3.6% | +27.6% | |
| Q4 2024 | -0.9% | -9.1% | -12.5% | |
| Q3 2024 | -2.3% | +0.2% | -15.4% | |
| Q1 2024 | -2.9% | -2.7% | +5.1% | |
| Q4 2023 | -4.9% | -9.2% | -13.5% | |
| Q3 2023 | -1.0% | -5.1% | +10.8% | |
| Q2 2023 | -2.5% | -2.0% | +3.4% | |
| Q1 2023 | +3.7% | -3.7% | -0.3% | |
| Q4 2022 | -1.8% | +2.0% | -11.6% | |
| Q3 2022 | +4.2% | +3.3% | +0.6% | |
| Q2 2022 | +0.4% | +1.7% | +6.1% | |
| Q1 2022 | -11.4% | -3.0% | -14.8% | |
| Q4 2021 | +5.5% | +1.5% | +6.5% | |
| Q3 2021 | +3.4% | +4.7% | -12.7% | |
| Q2 2021 | +5.1% | +3.6% | +3.1% | |
| Q1 2021 | +13.5% | +17.0% | +40.5% | |
| Q4 2020 | -21.5% | -11.9% | -17.3% | |
| Q3 2020 | +3.9% | -0.2% | -15.3% | |
| Q2 2020 | +23.8% | +31.0% | +5.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro